# To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

> **NCT01145768** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 72 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** TC-5214
- **DRUG:** TC-5214
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01145768
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2010-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01145768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01145768, "To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT01145768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*